Xcout Intel
Soligenix, Inc. competitors & alternatives
The 9 closest competitors and alternatives to Soligenix, Inc. among biopharmaceuticals companies — ranked by similarity to what Soligenix, Inc. actually does, not by market-cap band.
Subscribe to see Soligenix, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Soligenix, Inc.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
Soligenix, Inc. at a glance
Soligenix, Inc. is a biopharmaceuticals company headquartered in Princeton, United States. It is publicly listed (SNGX) with a market capitalisation of $5.9M. Xcout tracks 17 named people at Soligenix, Inc., including Christopher J. Schaber (Chairman of the Board of Directors, Chief Executive Officer & President).
Soligenix, Inc. leadership
- Christopher J. SchaberChairman of the Board of Directors, Chief Executive Officer & President
- Jonathan L. Guarino CGMASenior Vice President, Chief Financial Officer & Corporate Secretary
- Oreola DoniniSenior Vice President & Chief Scientific Officer
- Adam T. RumageSenior VP of Project Management & Regulatory Affairs
- Anthony Gregg LapointeDirector
- Christopher J. SchaberDirector
11 more named people on record for Soligenix, Inc., with roles, board committees and tenure — see the full roster →
Top 9 Soligenix, Inc. competitors
Ranked by semantic similarity — how close each company is to Soligenix, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biopharmaceuticals company
Emergent BioSolutions Inc. is a life sciences enterprise dedicated to developing and delivering solutions for preparing for and responding to diverse public health threats (PHTs) in the United States. Its mission involves countering unforeseen, intentional, and naturally arising health crises affecting populations. The company's product portfolio addresses a wide spectrum of PHTs, encompassing chemical, biological, radiological, nuclear, and explosive agents (CBRNE), emergent infectious diseases, travel-related health concerns, and immediate emergency medical needs. Among its key commercialized offerings are: Vaccines: BioThrax (for anthrax), ACAM2000 (for smallpox), Vivotif (an oral immunization against typhoid fever), and Vaxchora (a single-dose oral vaccine for cholera). Treatments & Antidotes: Botulism Antitoxin Heptavalent (combats botulism), vaccinia immune globulin intravenous (manages adverse reactions to smallpox vaccination), raxibacumab and Anthrasil (both for treating and preventing inhalational anthrax), and NARCAN (a nasal spray for immediate intervention in known or suspected opioid overdoses). Other Emergency Preparedness: Reactive skin decontamination lotion kits, and Trobigard, an investigational auto-injector product combining both drug and device components. Furthermore, Emergent BioSolutions boasts an active development pipeline, featuring candidates such as AP003 (a multidose Naloxone nasal spray), AP007 (a sustained-release Nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus-like particle vaccine), COVID-HIG (a treatment for SARS-CoV2), EGRD-001 (a diazepam auto-injector), SIAN (an antidote for acute cyanide poisoning), and UniFlu (a universal influenza vaccine). Beyond its proprietary products, the company also provides comprehensive contract development and manufacturing (CDMO) services. These services include drug substance and product manufacturing, packaging solutions, alongside specialized expertise in technology transfer, process optimization, and analytical development. Established in 1998, Emergent BioSolutions maintains its corporate headquarters in Gaithersburg, Maryland.
Similar biopharmaceuticals company
Chimerix, Inc. is a biopharmaceutical company that develops medicines for oncology and other critical illnesses, serving US-based healthcare audiences and patients.
Similar biopharmaceuticals company
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, dedicated to advancing therapies to treat rare diseases.
Similar biopharmaceuticals company
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company located in South San Francisco and Mountain View, California. The company focuses on oncology, leveraging its proprietary Pro-XTEN technology platform to engineer novel protein therapeutics.
Similar biopharmaceuticals company
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Similar biopharmaceuticals company
Cidara Therapeutics, Inc. is a biotechnology company focused on developing late-phase antiviral and immunotherapy agents, with operations based in San Diego, California and Rahway, New Jersey.
Similar biopharmaceuticals company
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Similar biopharmaceuticals company
CAGE Bio is a clinical-stage biotechnology company that develops localized therapies for dermatology, inflammation, and immunology. The company utilizes a proprietary deep eutectic ionic liquid platform to enable the skin penetration of small and large molecules, providing topical treatments designed to avoid the side effects of systemic drug exposure.
Similar biopharmaceuticals company
Citius Oncology is a biopharmaceutical company that develops and commercializes targeted oncology therapies. It serves patients with cancer, including its FDA-approved targeted immune therapy LYMPHIR for cutaneous T-cell lymphoma.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Soligenix, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Soligenix, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →